Main > A1. CORP. INDEX. Bn-Bz > Bristol Myers Squibb /P C2
This data is not available for free
Bristol Myers Squibb /P C2's subsections
2001. 12.17.2001. (Anxiolytics)
2002. 03.04.2002. (ImClone)
2002. 03.11.2002. (ImClone)
2002. 03.11.2002. (Neuro.>AD)
2002. 03.25.2002. (Supplier)
2002. 04.01.2002. (Patent Expir.)
2002. 04.22.2002. (Oncology)
2002. 05.13.2002. (Oncology)
2002. 05.23.2002. (Neurology)
2002. 05.27.2002. (Oncology)
2002. 06.10.2002. (Oncology-1)
2002. 06.10.2002. (Oncology-2)
2002. 07.01.2002. (Safety)
2002. 07.10.2002. (Oncology)
2002. 07.15.2002. (Oncology)
2002. 08.12.2002. (Oncology)
2002. 09.02.2002. (Collaboration)
2002. 09.23.2002. (Patent Expir.)
2002. 10.28.2002. (Contact)
2002. 10.28.2002. (R&D Staff Cuts)
2002. 10.28.2002. (Stock Price)
2002. 11.04.2002. (Oncology)
2002. 11.11.2002. (CombiChem)
2002. 11.18.2002. (Arthritis)
2002. 11.18.2002. (Drug Failure)
2002. 12.02.2002. (Market Share)
2002. 12.02.2002. (Metabonomics)
2002. 12.02.2002. (Neuro.)
2003. 01.13.2003. (Litigation Deal)
2003. 02.24.2003. (Antibiotics)
2003. 03.17.2003. (AIDS)
2003. 03.17.2003. (Earnings)
2003. 03.17.2003. (Executive)
2003. 03.17.2003. (FTC Settlement)
2003. 03.17.2003. (Process R&D)
2003. 03.17.2003. (Ranking)
2003. 03.17.2003. (Sales)
2003. 05.05.2003. (Statin)
2003. 05.05.2003. (Taxol Settle.)
2003. 05.26.2003. (Oncology)
2003. 06.01.2003. (ImClone)
2003. 06.16.2003. (Contract Mfg.)
2003. 06.20.2003. (AIDS)
2003. 08.20.2003. (AIDS)
2003. 09.15.2003. (Oncology)
2003. 10.06.2003. (Drug Deliv.)
2003. 11.27.2003. (Executive)
2004. 01.26.2004. (Iconix Pharma.)
2004. 02.12.2004. (Onco.)
2004. 03.15.2004. (Cardiology)
2004. 09.06.2004. (Buchwald Hartwi)
2005. 01.24.2005. (Ambit Bio Deal)
2005. 05.30.2005. (Anxiolytics)
2005. 05.30.2005. (Codexis Deal)
2005. 05.30.2005. (MicroChemistry)
2005. 10.31.2005. (AMRI)
2006. 05.18.2006. (Diab.)
2006. 08.14.2006. BioCatalysis
2006. 09.18.2006. General Counsel
2007. 01.22.2007. VP Proc. R&D
2007. 03.19.2007. IN>R&D Lab.
2007. 09.29.2007. (Claims Settlem.)
2007. 11.20.2007. (Psychiatry)
2008. 01.22.2008. (Exelixis)
2008. 02.06.2008. (AIDS)
2008. 02.22.2008. (Psychiatry)
2008. 03.05.2008. (Cardiology)
2008. 04.25.2008. (Onco.>Melanoma)
2008. 04.28.2008. (Onco.)
2008. 06.02.2008. (CEO)
2008. 07.07.2008. (Dako AS)
2008. 08.18.2008. (Tekmira Pharma.)
2008. 09.15.2008. (Onco.>Melanoma)
2008. 12.01.2008. (Onco.>Exelixis)
2009. 03.02.2009. (Hepato.>HCV)
2009. 04.23.2009. Diab.>DPP-IV Inh.
2009. 04.27.2009. Neuro.>AD
2009. 06.08.2009. Process R&D
2009. 11.20.2009. Autistic Disorder
2010. 03.03.2010. Pain Drug
2010. 04.17.2010. (Hepato.>HCV)
2010. 05.20.2010. Onco.>13 Compds.
2010. 06.14.2010. Icon & Parexel
2010. 11.03.2010. (Simcere Pharma.)
2010. 11.05.2010. Diab.>DPP-IV Inh.
2010. 12.20.2010. (AIDS)
2011. 02.02. Onco.>Lung C. Neci.
2011. 02.17.2011. Bipolar I Dis.
2011. 02.28.2011. (AIDS)
2011. 03.08.2011. WuXi PharmaTech
2011. 06.02.2011. Roche
2011. 07.06.2011. Innate Pharma
2011. 09.20.2011. Onco.>PD-1 MAb
2011. 09.22.2011. Ambrx
2011. 12.02.2011. Hepato.>HCV
2011. 12.13.2011. CV.>CETP Inh.
2012. 01.07. Acq. Inhibitex
2012. 01.19.2012. Diab.>NGLT2 Inh.
2012. 01.24.2012. BoD
2012. 02.28.2012. Duke Uni.>DTMI
2012. 03.28.2012. Neuro.>AD>Diag.
2012. 04.19.2012. Hepato.>HCV NS5A
2012. 04.19.2012. Hepato.>HCV PEG..
2012. 05.14.2012. Tsinghua Uni.
2012. 05.29.2012. Onco.>II-ON
2012. 06.04.2012. Nephro.
2012. 06.15.2012. Scripps Res.
2012. 06.20.2012. Emory Uni. Onco.
2012. 07.10.2012. PR Humacao Site
2012. 07.19.2012. Onco.>Liver C.
2012. 08.23.2012. Hepato.>HCV NS5B
2012. 09.21.2012. Neuro.>PD
2012. 10.01.2012. VP Bus. Dev.
2012. 10.03.2012. Sanofi
2012. 12.12.2012. Medicines Co.
2013. 02.12. Hepato.>HBV>Entecavir
2013. 02.12. Reckitt Benckiser
2013. 04.22. Onco.>BMS-906024
2013. 04.23. Hepato.>HCV>3DAA
2013. 05.15. Onco.>Melanoma I+N
2013. 06.14. Rheuma.>RA Aba
2013. 06.20. Onco.>CML Labelling
2013. 09.12. Onco.>Prostate C. I
2013. 10.28. Rheuma.>RA Cla
2013. 11.13. Changes Sr. Man. Team
2013. 12.11. LipoDystrophy
2014. 03.03. Onco.>ImmunoOncology
2014. 03.17. Five Prime Therap.
2014. 04.22. Samsung BioLogics
2014. 04.29. Acq. iPierian Inc.
2014. 05.19. Onco.>MM
2014. 05.27. CytomX Therapeutics
2014. 05.27. Onco.>Incyte
2014. 06.03. Syngene Intl.
2014. 06.12. Hepato.>HBV>Entecavir
2014. 06.24. Clin Trial Data Access
2014. 08.21. Blood Coag.
2014. 10.07. Hepato.>HCV>2DAA
2014. 10.28. Acq. F-star Alpha Ltd.
2014. 10.30. Lonza
2014. 11.03. Acq. Galecto Biotech
2014. 11.14. IE>Biologics Mfg. Fac.
2015. 01.05. Calibr
2015. 02.23. Acq. Flexus Bioscience
2015. 02.23. Rigel Pharma.
2015. 03.04. Onco.Prostate C. PSA
2015. 04.06. uniQure
2015. 06.19. Onco.>Melanoma N
2015. 06.25. Expands R&D
2015. 07.15. MUSC
2015. 07.16. AIDS
2015. 07.20. Onco.>Lung C. Nivo
2015. 07.24. Hepato>HCV>Daclatasvir
2015. 08.31. Promedior Inc
2015. 10.01. Onco.>Melanoma>I+N
2015. 10.15. Five Prime Therap.
2015. 11.02. Acq. Cardioxyl Pharma
2015. 11.23. Onco.>Renal C.>RCC
2016. 02.16. Dana-Farber Cancer
2016. 04.01. Acq. Padlock Therap.
2016. 05.11. Onco.>Melanoma>I+N
2016. 07.05. Acq. Cormorant Pharma
2016. 07.20. Rheuma.>RA Aba
2016. 11.10. Hepato.>NASH
2016. 11.16. Enterome
2016. 12.20. PsiOxus Therapeutics
2017. 01.20. Merck PD-1 Ab. Patent
2017. 02.02. Onco.>Bladder C.>mUC
2017. 03.01. Onco.>Blood C.>GRAIL
2017. 03.20. CytomX Therapeutics
2017. 04.13. Biogen, Roche
2017. 06.16. SK Biotek Co. Ltd.
2017. 08.01. Onco.>Colon C.
2017. 08.03. Acq. IFM Therapeutics
2018. 02.14. Nektar .. Onco.
2018. 04.16. Janssen Pharma.
2018. 11.06. Onco.>MM USA>OK
2019. 01.03. Acq. Celgene
2019. 01.14. Onco.>Kidney C.
2019. 08.27. Onco.>MM EU>OK
2019. 12.20. Onco.>Lymphoma>FL
2020. 02.04. Anteros Pharma.
2020. 02.21. Onco.>Esophageal C.
2020. 03.11. Onco.>HCC
2020. 03.26. Neuro.>RMS>USA>OK
2020. 04.03. Onco.>MDS>Anemia
2020. 05.15. Onco.>Kaposi Sarcoma
2020. 05.15. Onco.>NSCLC
2020. 05.26. Onco.>NSCLC
2020. 06.01. Neuro.>RMS>USA>Launch
2020. 06.26. Onco.>MDS>Anemia
2020. 08.11. Onco.>NSCLC
2020. 08.24. Acq. Forbius ..
2020. 09.01. Onco.>AML>USA>OK
2020. 09.29. Hemato.>β Thalass
2020. 10.02. Onco.>MPM
2020. 10.05. Acq. MyoKardia
2020. 11.06. Onco.>NSCLC
2020. 11.24. Onco.>ESCC
2021. 02.03. COVID-19 License
2021. 02.05. Onco.>LBCL>USA>OK
2021. 02.08. Onco.>Myelofibrosis>EU
2021. 03.26. Onco.>MM>USA>OK
2021. 06.17. Onco.>ADC>Eisai
2021. 06.18. Onco.>AML>EU>OK
2021. 08.19. Onco.>MM>EU>OK
2021. 08.20. Onco.>UC>USA>OK
2021. 12.15. aGvHD>USA>OK
2022. 03.04. Onco.>NSCLC>USA>OK
2022. 03.14. Onco.>Mela>Ph. 3
2022. 03.18. Onco.>Mela>USA>OK
2022. 04.28. Cardio.>Obstructiv HCM
2022. 05.27. Onco.>ESCC>USA>OK
2022. 06.03. Onco.>Acq. Turning Poi
2022. 06.24. Onco.>Lymphoma.USA>OK
2022. 08.17. Onco.>Acq. Turning Poi
2022. 09.09. Derma.>Psoriasis>USA>O
2022. 11.28. Derma.>Psoriasis>CA>OK
2023. 03.03. EU Approval
2023. 03.28. Derma.>Psoriasis>EU>OK
2023. 05.03. Onco.>Lymphoma.EU>OK
2023. 06.26. Cardio.>Obstructiv HCM
2023. 06.29. Onco.>NSCLC>EU>OK
2023. 10.08. Acq. Mirati Therap
2023. 10.30. Senior Unsecured Notes
2023. 11.06. ORM-6151 Program Acq.>
2023. 11.15. Onco.>NSCLC>USA>OK
2023. 12.12. SystImmune
2023. 12.22. Acq. Karuna Therapeuti
2023. 12.26. Acq. RayzeBio
2024. 01.23. Acq. Mirati Therap
2024. 02.26. Acq. RayzeBio
2024. 03.18. Acq. Karuna Therapeuti
2024. 10.03. Onco.>Resectable NSCLC
Patents
Web-Site
Z - OK
Bristol Myers Squibb /P C2's products
This section has no products